1. Home
  2. IVA vs MBX Comparison

IVA vs MBX Comparison

Compare IVA & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • MBX
  • Stock Information
  • Founded
  • IVA 2011
  • MBX 2018
  • Country
  • IVA France
  • MBX United States
  • Employees
  • IVA N/A
  • MBX N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • MBX
  • Sector
  • IVA Health Care
  • MBX
  • Exchange
  • IVA Nasdaq
  • MBX NYSE
  • Market Cap
  • IVA 359.6M
  • MBX 381.4M
  • IPO Year
  • IVA 2020
  • MBX 2024
  • Fundamental
  • Price
  • IVA $2.97
  • MBX $14.57
  • Analyst Decision
  • IVA Strong Buy
  • MBX Strong Buy
  • Analyst Count
  • IVA 4
  • MBX 6
  • Target Price
  • IVA $10.50
  • MBX $37.50
  • AVG Volume (30 Days)
  • IVA 15.3K
  • MBX 445.5K
  • Earning Date
  • IVA 09-24-2025
  • MBX 08-16-2025
  • Dividend Yield
  • IVA N/A
  • MBX N/A
  • EPS Growth
  • IVA N/A
  • MBX N/A
  • EPS
  • IVA N/A
  • MBX N/A
  • Revenue
  • IVA $14,591,573.00
  • MBX N/A
  • Revenue This Year
  • IVA $15.38
  • MBX N/A
  • Revenue Next Year
  • IVA $24.22
  • MBX N/A
  • P/E Ratio
  • IVA N/A
  • MBX N/A
  • Revenue Growth
  • IVA N/A
  • MBX N/A
  • 52 Week Low
  • IVA $1.53
  • MBX $4.81
  • 52 Week High
  • IVA $4.05
  • MBX $27.50
  • Technical
  • Relative Strength Index (RSI)
  • IVA 38.99
  • MBX N/A
  • Support Level
  • IVA $3.12
  • MBX N/A
  • Resistance Level
  • IVA $3.61
  • MBX N/A
  • Average True Range (ATR)
  • IVA 0.24
  • MBX 0.00
  • MACD
  • IVA -0.01
  • MBX 0.00
  • Stochastic Oscillator
  • IVA 13.95
  • MBX 0.00

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About MBX MBX BIOSCIENCES INC

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Share on Social Networks: